The way forward in HCV treatment — finding the right path

@article{Manns2008TheWF,
  title={The way forward in HCV treatment — finding the right path},
  author={Michael P. Manns and Graham R Foster and J{\"u}rgen K. Rockstroh and Stefan Zeuzem and Fabien Zoulim and Michael Houghton},
  journal={Nature Reviews Drug Discovery},
  year={2008},
  volume={7},
  pages={102-102}
}
Infection with the hepatitis C virus (HCV) represents an important health-care problem worldwide. The prevalence of HCV-related disease is increasing, and no vaccine is yet available. Since the identification of HCV as the causative agent of non-A, non-B hepatitis, treatment has progressed rapidly, but morbidity and mortality rates are still predicted to rise. Novel, more efficacious and tolerable therapies are urgently needed, and a greater understanding of the viral life cycle has led to an… 
Emerging therapies for hepatitis C virus
TLDR
Data from clinical trials are encouraging and suggest that combination therapies of these novel agents may have the potential to shorten treatment duration and increase viral clearance when used in conjunction with pegylated IFN-α and ribavirin.
HCV NS5B polymerase inhibitors.
A review on an update of NS5B polymerase hepatitis C virus inhibitors.
TLDR
This review gives the detailed knowledge of upcoming therapy such as NS5B polymerase inhibitors that are urgently needed for the treatment of the HCV infected patients.
How to optimize HCV therapy in genotype 4 patients
TLDR
Optimize treatment is the goal of daily practice to obtain the best results for the patient with Hepatitis C virus 4.
Development of boceprevir: a first‐in‐class direct antiviral treatment for chronic hepatitis C infection
TLDR
The discovery and development of a first‐in‐class direct antiviral treatment for chronic hepatitis C infection, boceprevir, marketed around the world as VictrelisTM is described.
Immunotherapy for HCV infection: next steps
TLDR
Treatment issues combined with new concepts in immune therapy serve to underscore an urgent need for the development of improved immunotherapies, such as novel interferons, and support the possible development of therapeutic vaccines for the treatment of chronic HCV infection.
New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy
TLDR
These new antiviral agents are expected to improve present treatment significantly and may potentially shorten treatment duration and the aim of this review is to summarize the current developments in new anti-HCV drugs.
The future for the treatment of genotype 4 chronic hepatitis C
TLDR
New types of interferon and new direct action antiviral drugs (Nitazoxanide, Vit.D, other) may improve the treatment of patients with HCV‐4 and the IL28B CC polymorphism may be associated with sustained virological response.
The Future of HCV Therapy: NS4B as an Antiviral Target
TLDR
This review summarizes potential targets within the nonstructural protein NS4B, with a focus on novel classes of NS3 protease or NS5B polymerase inhibitors.
...
...

References

SHOWING 1-10 OF 105 REFERENCES
Hepatitis C therapeutics: current status and emerging strategies
TLDR
The development of effective HCV antiviral therapeutics continues to be a daunting challenge owing to the absence of adequate animal models and tissue-culture systems for analysis and propagation of the virus.
Challenges and successes in developing new therapies for hepatitis C
TLDR
Preclinical evidence is accumulating that development of resistance will eventually limit the efficacy of new drugs, and combinations of multiple agents will be required to treat chronic HCV infection.
Treating viral hepatitis C: efficacy, side effects, and complications
TLDR
The efficacy and optimisation of the current standard therapy of hepatitis C and its problems in special patient populations are described.
Future Therapies for Hepatitis C
TLDR
This review focuses on four classes of new agents: new interferons, ribavirin-like molecules, specific small-molecule hepatitis C virus inhibitors and new immune therapies, with particular emphasis on medications in the later stages of development.
Structural biology of hepatitis C virus
TLDR
Structural analyses of HCV components provide an essential framework for understanding of the molecular mechanisms ofHCV polyprotein processing, RNA replication, and virion assembly and may contribute to a betterUnderstanding of the pathogenesis of hepatitis C.
Sustained Virologic Response in Hepatitis C
  • Medicine
    Annals of Internal Medicine
  • 2007
TLDR
Effective treatment of HCV infection seems to prevent the complications of chronic infection, which has never been demonstrated before.
The nature of interferon-alpha resistance in hepatitis C virus infection.
  • J. Pawlotsky
  • Biology, Medicine
    Current opinion in infectious diseases
  • 2003
TLDR
In spite of active research, the role and the mechanisms of IFN resistance in HCV persistence and IFN treatment failure remain partly unknown and a better understanding is needed in order to further improveIFN treatment strategies.
Prospects for a vaccine against the hepatitis C virus
The recent discovery of natural immunity to the hepatitis C virus and vaccine efficacy in the chimpanzee challenge model has allowed optimism about the development of at least a partly effective
Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27–March 1, 2003
TLDR
The preface and aims of the conference were to provide investigators with new knowledge and some of the necessary tools to aid in planning future rational clinical trial design in this rapidly changing field.
...
...